Response to Comment on: "Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential" [0.03%]
关于"Mmrn1表达定义了一种新型的造血干细胞和白血病干细胞具有很强的自我更新潜能"一文的回复
Naicheng Chen,Junping Wang,Mengjia Hu
Naicheng Chen
Not available.
Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap [0.03%]
通过国际真实世界数据合作改善淋巴瘤预后：全球淋巴瘤登记联盟路线图
Eliza A Hawkes,Eliza Chung,Mark J Bishton et al.
Eliza A Hawkes et al.
Lymphomas comprise a complex and heterogeneous group of malignancies which pose challenges in understanding their epidemiology, pathobiology, treatment responses and long-term outcomes. Evolving diagnostic classification and fast-paced ther...
Response to Comment on: "SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia" [0.03%]
对评论的回应：“SLC25A1重塑线粒体和脂肪酸代谢以促进急性髓系白血病进展”
Miao Chen,Ziyi Wang,Xiaojing Yan
Miao Chen
Not available.
Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy [0.03%]
Hanan Jaber,Anas Abu Khalaf,Lola Weiss et al.
Hanan Jaber et al.
Chimeric antigen receptor (CAR) T cell therapies have revolutionized treatment of hematologic malignancies such as lymphoma and multiple myeloma. However, their success is limited by high manufacturing costs, reliance on autologous T cells,...
ATRA resistance conferred by a clustered subset of hotspot PML::RARA mutations enhancing basal repression rather than precluding transactivation [0.03%]
由一组热点PML::RARA簇状突变赋予的砷抵抗，增强了基础抑制而不是阻止了活化作用
Glauce M Barbosa,Hao Yuan,Izabella Tambones et al.
Glauce M Barbosa et al.
Most acute promyelocytic leukemia (APL), driven by the PML::RARA fusion, are now cured with targeted therapies combining all-trans retinoic acid (ATRA) and arsenic trioxide. Some patients treated with earlier ATRA/chemotherapy regimen devel...
Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation [0.03%]
RUNX1基因突变在急性髓系白血病诊断时的预后价值及其作为异基因造血干细胞移植前后可测量残留病标志物的价值
Donata Backhaus,Lara Bischof,Jacob Jendro et al.
Donata Backhaus et al.
Not available.
Ido Somekh,Raz Somech
Ido Somekh
Not available.
Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy [0.03%]
巨噬细胞迁移抑制因子通过髓源性抑制细胞免疫抑制和主要组织相容性复合物I类下调促进多发性骨髓瘤的免疫逃逸：靶向治疗的启示
Jingjing Wen,Jingcao Huang,Juan Xu et al.
Jingjing Wen et al.
Macrophage migration inhibitory factor (MIF), derived from either tumor cells or the tumor microenvironment, promotes multiple myeloma (MM) progression by suppressing T cell-mediated antitumor responses. Here, we demonstrate that MIF drives...
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications [0.03%]
KSR2是TAL1亚型T细胞急性淋巴细胞白血病中的新型癌基因，具有潜在的临床和预后意义
Monika Drobna-Śledzińska,Natalia Maćkowska-Maślak,Roman Jaksik et al.
Monika Drobna-Śledzińska et al.
Not available.
Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes [0.03%]
基于免疫球蛋白的检测在大型B细胞淋巴瘤治疗后循环肿瘤DNA真实世界结果中的应用研究
Patrick Gould,Devyn Coskey,Xin Ma et al.
Patrick Gould et al.
Measurable residual disease (MRD) analysis using circulating tumor DNA (ctDNA) is a noninvasive method of response assessment in large B-cell lymphoma (LBCL), but data supporting its real-world feasibility and performance are needed. We con...